TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01006122
Drug: PF-03654746
Normalized name: PF-03654746
DrugBank: PF-03654746 (DB12201)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive PF-03654746 tablets in a fixed dose titration schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at the 1.0 mg dose; decrease to 0.50 mg or increase to 2.0 mg based upon the clinician's judgement regarding efficacy and side effects at the 1.0 mg dose. The patient will remain at the determined dose for a 3 week stable dosing period.
Study: NCT02648139
Drug: Dentifrice
Normalized name: DENTIFRICES
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x/day for 7 days.
Study: NCT02655822
Drug: Ciforadenant
Normalized name: Ciforadenant
DrugBank: Ciforadenant (DB16125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg orally twice daily for the first 14 days of each 28-day cycle.
Study: NCT02655822
Drug: Ciforadenant
Normalized name: Ciforadenant
DrugBank: Ciforadenant (DB16125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg orally twice daily for 28 days of each 28-day cycle.
Study: NCT02655822
Drug: Ciforadenant
Normalized name: Ciforadenant
DrugBank: Ciforadenant (DB16125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg orally once daily for the first 14 days of each 28-day cycle.
Study: NCT02655822
Drug: Ciforadenant + atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ciforadenant 100 mg orally twice daily in combination with atezolizumab intravenously.
Study: NCT02655822
Drug: Ciforadenant
Normalized name: Ciforadenant
DrugBank: Ciforadenant (DB16125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start with 150mg orally twice daily for 28-day cycles; then, increase increments by 100mg/day for 6 dose levels.
Study: NCT00002943
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002943
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04485325
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg twice daily, p.o.
Study: NCT03660930
Drug: Sirolimus Albumin-bound Nanoparticles
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT03660930
Drug: Pazopanib hydrochloride
Normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02996825
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02996825
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04217096
Drug: Paclitaxel liposome
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receive paclitaxel liposome 175 mg/m\^2 (iv, 3h) on day 1 for 3 weeks. Treatment repeats every 3 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic
Study: NCT04217096
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Patients receive S-1 at a dose according to the body surface area（\<1.25m\^2，40mg Bid；1.25\~1.5m\^2,50mg Bid；\>1.50m\^2,60mg Bid）on days 1-14 for 3 weeks. Treatment repeats every 3 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
Study: NCT01559077
Drug: ALN-TTR02
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose levels between 0.01 and 0.5 mg/kg by intravenous (IV) infusion
Study: NCT01559077
Drug: Sterile Normal Saline (0.9% NaCl)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated volume to match active comparator
Study: NCT03493854
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As part of one of the two investigator's choices of chemotherapy (AC followed by docetaxel), docetaxel 75 mg/m2 will be administered IV on Day 1 of Cycle 5 and then 100 mg/m2 IV at the discretion of the investigator for Cycles 6-8 (Q3W), if no dose-limiting toxicity occurs.
Study: NCT03493854
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As part of one of the two investigator's choices of chemotherapy (ddAC followed by paclitaxel), paclitaxel 80 mg/m2 will be administered IV QW for 12 weeks.
Study: NCT03493854
Drug: Pertuzumab IV
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab will be administered as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.
Study: NCT03493854
Drug: FDC of Pertuzumab and Trastuzumab SC
Normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The FDC of pertuzumab and trastuzumab will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.
Study: NCT03493854
Drug: Trastuzumab IV
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab will be administered as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
Study: NCT03493854
Drug: Trastuzumab SC
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After surgery (from Cycle 9 onwards), participants in Arm A will be allowed to switch from trastuzumab IV to trastuzumab SC, at the discretion of the investigator, in the countries where trastuzumab SC is routinely used. For participants who switch, a fixed dose of 600 mg trastuzumab SC (irrespective of the patient's weight) will be administered in the adjuvant phase.
Study: NCT02597439
Drug: Omega-3 fatty acids
Normalized name: Omega-3 Fatty Acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02422446
Drug: Icosapent ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: icosapent ethyl is eicosapentaenoic acid, an omega-3 fatty acid that naturally occurs in fish
Study: NCT02094352
Drug: Ketamine Infusion + Epidural Infusion
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The ketamine and epidural infusions will be administered over 96 hours with appropriate titration.
Study: NCT02094352
Drug: Ketamine Booster Infusion
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive three ketamine booster infusions over the course of three months.
Study: NCT00739661
Drug: Vismodegib 150 mg
Normalized name: vismodegib 150 MG
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vismodegib 150 mg was provided in hard gelatin capsules.
Study: NCT00739661
Drug: Placebo to vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
Study: NCT04168723
Drug: Moxifloxacin 400mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group B1: Moxifloxacin 400 mg on Day 1 Group B2: Moxifloxacin 400 mg on Day 9
Study: NCT03086330
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
Study: NCT04168723
Drug: Placebo for moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A: Placebo for moxifloxacin on Day 1 and Day 9 Group B1: Placebo for moxifloxacin on Day 9 Group B2: Placebo for moxifloxacin on Day 1
Study: NCT02691949
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: mycophenolate mofetil 1# BID-2# BID
Study: NCT00954941
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy.
Study: NCT00954941
Drug: Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 125 mg capsule by mouth every morning while receiving chemotherapy followed by 80 mg capsule by mouth daily while receiving chemotherapy continued till 1 day after last chemotherapy dose.
Study: NCT00271063
Drug: Liposomal Annamycin
Normalized name: Annamycin
DrugBank: Annamycin (DB06420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day IV infusion
Study: NCT01315938
Drug: Abatacept Active Treatment
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will be treated with abatacept by intravenous infusions a total of seven times at week(s) 0, 2, 4, 8, 12, 16 and 20 weeks.
Study: NCT01315938
Drug: Abatacept Delayed-Onset Treatment
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will be treated with abatacept for 6 months and received a total of seven intravenous infusions at weeks 12, 14, 16, 20, 24, 28 and 32.
Study: NCT04245436
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Encapsulated duloxetine 30 mg, 60 mg; once-daily
Study: NCT04245436
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Encapsulated escitalopram 5 mg, 10 mg, 15 mg, 20 mg; once-daily
Study: NCT01357317
Drug: Phosphorus binder
Normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If serum phosphorus level exceeds 4.6 mg/dl after 3 months of concerted efforts, the patient will be considered a treatment failure and treatment with a phosphorus binder of the treating physician's choice will be allowed.
Study: NCT00765102
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib was administered at a dose of 1.0 mg/m\^2 as an intravenous (IV) push over 3 to 5 seconds twice weekly for 2 consecutive weeks (Days 1, 4, 8 and 11) of each 28-day cycle. On days that bortezomib and romidepsin were administered together, bortezomib was administered prior to the romidepsin infusion.~Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles.
Study: NCT00765102
Drug: Romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin initially was administered at a dose of 10 mg/m\^2 as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. Based on the occurrence of Grade 3 thrombocytopenia at this dose level, the dose was reduced by protocol amendment to 8 mg/m\^2.
Study: NCT00828568
Drug: Imiquimod 5% manufactured by Taro
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
Study: NCT00828568
Drug: Aldara - Imiquimod 5%
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
Study: NCT00828568
Drug: Imiquimod Vehicle manufactured by Taro
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment applied as a thin layer to target area once daily, 2 days each week, for 16 weeks
Study: NCT01155908
Drug: Amlodipine Besylate / Benazepril Hydrochloride
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
Study: NCT01757535
Drug: Oral Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg oral azacitidine on days 1 to 14 of each 28-day treatment cycle.
Study: NCT01780519
Drug: lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of 1 mg lorazepam
Study: NCT00403481
Drug: olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil tablets, once daily
Study: NCT00634803
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: buprenorphine/naloxone
Study: NCT01672554
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
Study: NCT06041451
Drug: Methylprednisolone 500 MG Injection
Normalized name: methylprednisolone 500 MG Injection
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients were treated with methylprednisolone
Study: NCT02684097
Drug: Tralokinumab
Normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All groups will receive study drug every two weeks for 24 weeks.
Study: NCT00204698
Drug: Aciphex
Normalized name: Aciphex
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg of aciphex taken twice daily
Study: NCT03208998
Drug: Peginterferon Alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
Study: NCT02821754
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Flat dose of 1500 mg every 4 weeks.
Study: NCT02821754
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flat dose of 75 mg every 4 weeks for up to 4 doses.
Study: NCT00379717
Drug: Cisplatinum
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00379717
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04299815
Drug: Oral Sodium Lactate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 grams of D/L lactate dissolved in 300mL water.
Study: NCT04299815
Drug: Intravenous sodium lactate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous sodium lactate + oral sodium-chlorid solution
Study: NCT02056210
Drug: Mozobil
Normalized name: Mozobil
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection of 0.24 mg/kg Mozobil once at 8:30am
Study: NCT03507634
Drug: Opioid free Anesthesia dexmedetomidine and lidocaine
Normalized name: codeine and other non-opioid analgesics
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opioid free anesthesia with dexmedetomidine and lidocaine
Study: NCT00033722
Drug: lometrexol
Normalized name: Lometrexol
DrugBank: Lometrexol (DB12769)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00852059
Drug: Immediate release methylphenidate (Medikinet®)
Normalized name: methylphenidate Extended Release Suspension
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment: methylphenidate in the morning and 3-4 h later (twice daily), immediate release
Study: NCT00852059
Drug: Extended release methylphenidate (Medikinet retard®)
Normalized name: methylphenidate Extended Release Suspension
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment: methylphenidate applied with breakfast(once daily), extended release
Study: NCT00396071
Drug: vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: vildagliptin 100 mg
Study: NCT04530188
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)
Study: NCT04530188
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous sedation with propofol, as already used in our ICU
Study: NCT00252291
Drug: Aridol
Normalized name: Aridol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00252291
Drug: Methacholine
Normalized name: Methacholine
DrugBank: Methacholine (DB06709)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00660244
Drug: anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT01583062
Drug: Amoxicillin/clavulanic acid
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 1 then receives amoxicillin/clavulanic acid 625 mg orally every eight hours for four days.
Study: NCT01583062
Drug: Amoxicillin plus placebo
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.
Study: NCT01277627
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nevirapine: 400 mg a day.
Study: NCT01277627
Drug: efavirenz, protease inhibitors
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efavirenz: 600 mg a day
Study: NCT00571727
Drug: mecasermin
Normalized name: mecasermin
DrugBank: Mecasermin (DB01277)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: injections BID of rhIGF-1, mecasermin
Study: NCT01776437
Drug: BMN 673
Normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mcg dose of BMN 673, 2 discrete single doses separated by 21 days
Study: NCT03955705
Drug: Nefopam 20 mg/ml
Normalized name: nefopam 20 MG/ML
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam is a benzoxazocine derivative which is non-opioid and non NSAIDs. The previous studies showed that nefopam can inhibit reuptake of serotonin, norepinephrine and dopamine.
Study: NCT02576080
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00810667
Drug: Lu AE58054
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily oral dose (60 mg BID: total dose 120 mg/day)
Study: NCT03391219
Drug: injection bevacizumab
Normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.25 mg/0.05 cc bevacizumab
Study: NCT03391219
Drug: injection Combined Bevacizumab and Fasudil
Normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.25 mg/0.05 cc bevacizumab and 0.15mg/0.05 cc fasudil
Study: NCT01775813
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After randomization, the study drug (metformin or placebo) is gradually titrated to full dose of 1000 mg BID (or to maximum tolerated, at least 500 mg BID) over a period of 4 weeks to minimize adverse gastrointestinal effects. Participants are seen every three months to measure compliance and dispense new study drug. Every 6 months, they also have a physical examination in order to determine puberty staging. Study measurements (IVGTT, bloodwork, DXA) are performed at Tanner 4 puberty and Tanner 5 (puberty completion), at which time the study drug is stopped. Study measurements will be performed again 6 months after study drug is completed to assess if effects are persistent after study drug is stopped. During the treatment period, all participants receive standard lifestyle counseling.
Study: NCT02496078
Drug: Daclatasvir
Normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir tablet 60mg
Study: NCT02496078
Drug: Asunaprevir
Normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Asunaprevir soft capsule 100 mg
Study: NCT04168112
Drug: Dextenza
Normalized name: Dextenza
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placement of intracanalicular dexamethasone insert for post-crosslinking inflammation and pain
Study: NCT02680808
Drug: Midazolam with F901318
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmacokinetics of midazolam with F901318
Study: NCT03768908
Drug: Artesunate + Amodiaquine
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three day treatment with Artesunate + Amodiaquine, co-administered, a dose a day under direct observation
Study: NCT01130376
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 Million Units administered twice daily for 5 days by subcutaneous injection on days 7, 8, 9, 10, and 11 after first vaccination. .